133 related articles for article (PubMed ID: 10583162)
1. Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers.
Grimme HU; Termeer CC; Bennett KL; Weiss JM; Schöpf E; Aruffo A; Simon JC
Br J Dermatol; 1999 Nov; 141(5):824-32. PubMed ID: 10583162
[TBL] [Abstract][Full Text] [Related]
2. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor.
Bennett KL; Jackson DG; Simon JC; Tanczos E; Peach R; Modrell B; Stamenkovic I; Plowman G; Aruffo A
J Cell Biol; 1995 Feb; 128(4):687-98. PubMed ID: 7532176
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.
van der Voort R; Taher TE; Wielenga VJ; Spaargaren M; Prevo R; Smit L; David G; Hartmann G; Gherardi E; Pals ST
J Biol Chem; 1999 Mar; 274(10):6499-506. PubMed ID: 10037743
[TBL] [Abstract][Full Text] [Related]
4. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
Jackson DG; Bell JI; Dickinson R; Timans J; Shields J; Whittle N
J Cell Biol; 1995 Feb; 128(4):673-85. PubMed ID: 7532175
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of basic fibroblast growth factor in skin diseases.
Yaguchi H; Tsuboi R; Ueki R; Ogawa H
Acta Derm Venereol; 1993 Apr; 73(2):81-3. PubMed ID: 8103271
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours.
Karvinen S; Kosma VM; Tammi MI; Tammi R
Br J Dermatol; 2003 Jan; 148(1):86-94. PubMed ID: 12534600
[TBL] [Abstract][Full Text] [Related]
7. Distinct CD44 splice variants differentially affect collateral artery growth.
Bot PT; Grundmann S; van Royen N; Joosten SP; Schirmer SH; de Kleijn DP; Pals ST; Pasterkamp G; Piek JJ; Hoefer IE
Curr Vasc Pharmacol; 2013 Jan; 11(1):13-20. PubMed ID: 23391418
[TBL] [Abstract][Full Text] [Related]
8. Generation of artificial proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction between rantes and chondroitin sulfate.
Wolff EA; Greenfield B; Taub DD; Murphy WJ; Bennett KL; Aruffo A
J Biol Chem; 1999 Jan; 274(4):2518-24. PubMed ID: 9891023
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfate in the inner limiting membrane of embryonic chicken retina binds basic fibroblast growth factor to promote axonal outgrowth.
Chai L; Morris JE
Exp Neurol; 1999 Nov; 160(1):175-85. PubMed ID: 10630202
[TBL] [Abstract][Full Text] [Related]
10. CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.
Tempfer C; Sliutz G; Haeusler G; Speiser P; Reinthaller A; Breitenecker G; Vavra N; Kainz C
Br J Cancer; 1998 Oct; 78(8):1091-4. PubMed ID: 9792156
[TBL] [Abstract][Full Text] [Related]
11. Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells.
Nugent MA; Karnovsky MJ; Edelman ER
Circ Res; 1993 Dec; 73(6):1051-60. PubMed ID: 8222077
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
[TBL] [Abstract][Full Text] [Related]
13. Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor.
Habuchi H; Suzuki S; Saito T; Tamura T; Harada T; Yoshida K; Kimata K
Biochem J; 1992 Aug; 285 ( Pt 3)(Pt 3):805-13. PubMed ID: 1497618
[TBL] [Abstract][Full Text] [Related]
14. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3.
Kuniyasu H; Oue N; Tsutsumi M; Tahara E; Yasui W
Clin Cancer Res; 2001 Dec; 7(12):4067-72. PubMed ID: 11751503
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CD44v3-containing isoforms in head and neck cancer.
Reategui EP; de Mayolo AA; Das PM; Astor FC; Singal R; Hamilton KL; Goodwin WJ; Carraway KL; Franzmann EJ
Cancer Biol Ther; 2006 Sep; 5(9):1163-8. PubMed ID: 16855392
[TBL] [Abstract][Full Text] [Related]
16. Growth of normal human keratinocytes and fibroblasts in serum-free medium is stimulated by acidic and basic fibroblast growth factor.
Shipley GD; Keeble WW; Hendrickson JE; Coffey RJ; Pittelkow MR
J Cell Physiol; 1989 Mar; 138(3):511-8. PubMed ID: 2466852
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor-binding protein expression changes with disease progression in clinical and experimental human squamous epithelium.
Sauter ER; Nesbit M; Tichansky D; Liu ZJ; Shirakawa T; Palazzo J; Herlyn M
Int J Cancer; 2001 May; 92(3):374-81. PubMed ID: 11291074
[TBL] [Abstract][Full Text] [Related]
18. A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression.
Kalish ED; Iida N; Moffat FL; Bourguignon LY
Front Biosci; 1999 Jan; 4():A1-8. PubMed ID: 9872731
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment with basic fibroblast growth factor promotes wound healing and barrier recovery induced by skin abrasion.
Nakamizo S; Egawa G; Doi H; Natsuaki Y; Miyachi Y; Kabashima K
Skin Pharmacol Physiol; 2013; 26(1):22-9. PubMed ID: 23108135
[TBL] [Abstract][Full Text] [Related]
20. Keratinocyte growth factor receptor ligands induce transforming growth factor alpha expression and activate the epidermal growth factor receptor signaling pathway in cultured epidermal keratinocytes.
Dlugosz AA; Cheng C; Denning MF; Dempsey PJ; Coffey RJ; Yuspa SH
Cell Growth Differ; 1994 Dec; 5(12):1283-92. PubMed ID: 7535082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
